Efficacy and tolerability of intravenous levetiracetam in children

Jose Aceves, Owais Khan, Diana Mungall, Ekokobe Fonkem, Chanin Wright, Andrea Wenner, Batool Kirmani

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Intractable epilepsy in children poses a serious medical challenge. Acute repetitive seizures and status epilepticus leads to frequent emergency room visits and hospital admissions. Delay of treatment may lead to resistance to the first-line anticonvulsant therapies. It has been shown that these children continue to remain intractable even after acute seizure management with approved Food and Drug Administration (FDA) agents. Intravenous levetiracetam, a second-generation anticonvulsant was approved by the FDA in 2006 in patients 16 years and older as an alternative when oral treatment is not an option. Data have been published showing that intravenous levetiracetam is safe and efficacious, and can be used in an acute inpatient setting. This current review will discuss the recent data about the safety and tolerability of intravenous levetiracetam in children and neonates, and emphasize the need for a larger prospective multicenter trial to prove the efficacy of this agent in acute seizure management.

Original languageEnglish (US)
Article numberArticle
JournalFrontiers in Neurology
Volume4 AUG
StatePublished - 2013
Externally publishedYes


  • Children
  • Epilepsy
  • Intractable epilepsy
  • Intravenous levetiracetam
  • Seizures
  • Status epilepticus

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Efficacy and tolerability of intravenous levetiracetam in children'. Together they form a unique fingerprint.

Cite this